Drugs / BI 1291583
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT07023354 | Jul 2025 → Dec 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06917872 | Apr → Sep 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06791187 | Jan → Feb 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06631417 | Oct 2024 → Jan 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06166992 | Dec 2023 → Feb 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05833035 | Apr → Jul 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05183347 | Feb → Jul 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04866160 | May → Nov 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03890887 | Apr → Jul 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03868540 | Mar → Nov 2019 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT03837964 | Feb → Apr 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03414008 | Feb 2018 → Nov 2019 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT05865886 | Apr → Oct 2024 | bronchiectasis, cystic fibrosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT05846230 | Sep 2023 → Mar 2027 expected | bronchiectasis | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05238675 | Apr 2022 → May 2024 | bronchiectasis | Boehringer Ingelheim | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06872892 | Jun 2025 → Jun 2027 expected | bronchiectasis | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1291583 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05865886 ↗ |
| Action | Inhibit | “BI 1291583, a novel, reversible CatC inhibitor” PMID 39255990 ↗ Jan 2025 |
| Route | Oral | “following oral administration of single rising doses” NCT03414008 ↗ |
| Target | CTSC | “BI 1291583 inhibited CatC in a dose-dependent manner” PMID 39175217 ↗ Aug 2024 |